Complete Filing Data
DR REDDYS LABORATORIES LTD reported Cash And Cash Equivalents If Different From Statement Of Financial Position of $14.59 billion for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean DR REDDYS LABORATORIES LTD did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Share Of Profit Loss Of Joint Ventures Accounted For Using Equity Method | $217.0M | $147.0M | $370.0M | $703.0M | $480.0M | $561.0M | $438.0M | $344.0M | $349.0M |
| Selling General And Administrative Expense | $1.10B | $77.20B | $68.03B | $62.08B | $54.65B | $50.13B | $48.68B | $46.86B | $46.37B |
| Research And Development Expense | $320.0M | $22.87B | $19.38B | $17.48B | $16.54B | $15.41B | $15.61B | $18.27B | $19.55B |
| Profit Loss From Operating Activities | $842.0M | $67.73B | $57.14B | $29.48B | $24.28B | $15.99B | $20.89B | $11.92B | $13.50B |
| Profit Loss Before Tax | $76.78B | $71.87B | $60.37B | $32.30B | $26.41B | $18.03B | $22.44B | $14.34B | $14.65B |
| Profit Loss | $57.25B | $55.68B | $45.07B | $23.57B | $17.24B | $19.50B | $18.80B | $9.81B | $12.04B |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax | -$3.0M | -$24.0M | -$730.0M | -$3.26B | $3.81B | -$434.0M | -$807.0M | $27.0M | -$25.0M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax | $2.21B | -$665.0M | $341.0M | $380.0M | $1.52B | -$415.0M | -$41.0M | -$3.88B | $2.43B |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements Of Defined Benefit Plans | -$94.0M | -$10.0M | $57.0M | -$34.0M | -$216.0M | $57.0M | $10.0M | $39.0M | -$39.0M |
| Other Comprehensive Income | $1.95B | -$689.0M | -$389.0M | -$2.88B | $5.32B | -$849.0M | -$848.0M | -$3.85B | $2.40B |
| Income Taxes Paid Classified As Operating Activities | $19.99B | $20.05B | $10.71B | $7.44B | $5.72B | $7.11B | $4.84B | $2.76B | $5.77B |
| Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | -$24.0M | -$4.0M | $69.0M | -$305.0M | $220.0M | $22.0M | $414.0M | $12.0M | -$14.0M |
| Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | $58.0M | -$117.0M | -$306.0M | $288.0M | $319.0M | -$232.0M | $55.0M | -$1.39B | $411.0M |
| Income Tax Expense Continuing Operations | $19.54B | $16.19B | $15.30B | $8.73B | $9.18B | -$1.47B | $3.65B | $4.54B | $2.61B |
| Gross Profit | $2.23B | $163.61B | $139.34B | $113.84B | $103.08B | $94.01B | $83.43B | $76.30B | $78.36B |
| Cost Of Sales | $1.58B | $115.56B | $106.54B | $100.55B | $86.65B | $80.59B | $70.42B | $65.72B | $62.45B |
| Comprehensive Income | $694.0M | $55.00B | $44.68B | $20.69B | $22.56B | $18.65B | $17.95B | $5.95B | $14.44B |
| Adjustments For Income Tax Expense | $19.54B | $16.19B | $15.30B | $8.73B | $9.18B | -$1.47B | $3.65B | $4.54B | $2.61B |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | $20.0M | $3.0M | $699.0M | $7.56B | $8.59B | $16.77B | $210.0M | $53.0M | $445.0M |
| Share Of Profit Loss Of Associates Accounted For Using Equity Method | $3.0M | $147.0M | $370.0M | $703.0M | $480.0M | $561.0M | $438.0M | $344.0M | |
| Other Comprehensive Income Net Of Tax Gains Losses On Remeasurements Of Defined Benefit Plans | -$70.0M | -$6.0M | -$12.0M | -$22.0M | -$143.0M | $35.0M | $7.0M | $27.0M | -$25.0M |
| Interest Revenue Expense | -$152.0M | $567.0M | -$248.0M | $7.0M | -$144.0M | -$95.0M | -$119.0M | $248.0M | |
| Income Tax Relating To Remeasurements Of Defined Benefit Plans Of Other Comprehensive Income | -$24.0M | -$4.0M | $69.0M | -$12.0M | -$73.0M | -$22.0M | $3.0M | $12.0M | -$14.0M |
| Income Tax Relating To Cash Flow Hedges Of Other Comprehensive Income | $58.0M | -$117.0M | -$354.0M | $288.0M | $319.0M | -$232.0M | $69.0M | -$41.0M | $60.0M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents If Different From Statement Of Financial Position | $14.59B | $7.11B | $5.78B | $14.85B | $14.82B | $1.96B | $2.23B | $2.54B | $3.78B | $4.92B |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $27.50B | $16.40B | $11.32B | $14.66B | $9.74B | $4.85B | $6.96B | $9.29B | $12.28B | |
| Purchase Of Investments Other Than Investments Accounted For Using Equity Method | $254.46B | $145.49B | $136.17B | $88.97B | $75.42B | $111.92B | $78.57B | $68.43B | $49.65B | |
| Purchase Of Intangible Assets Classified As Investing Activities | $81.0M | $11.03B | $7.54B | $4.39B | $2.82B | $1.27B | $1.42B | $1.75B | $28.71B | |
| Intangible Assets Other Than Goodwill | $1.13B | $36.95B | $30.85B | $27.25B | $35.65B | $27.66B | $44.37B | $44.67B | $44.93B | |
| Gains Losses On Cash Flow Hedges Before Tax | $2.43B | -$470.0M | -$905.0M | $882.0M | $1.12B | -$951.0M | $180.0M | -$82.0M | $968.0M | |
| Cash Flows From Used In Operations | $779.0M | $65.48B | $69.59B | $35.55B | $41.42B | $36.95B | $33.55B | $20.79B | $27.28B | |
| Cash Flows From Used In Operating Activities | $46.43B | $45.43B | $58.88B | $28.11B | $35.70B | $29.84B | $28.70B | $18.03B | $21.51B | |
| Cash Flows From Used In Investing Activities | -$58.08B | -$40.28B | -$41.37B | -$26.39B | -$22.66B | -$4.92B | -$7.73B | -$14.88B | -$18.47B | |
| Cash Flows From Used In Financing Activities | $18.91B | -$3.76B | -$26.86B | -$2.42B | -$298.0M | -$25.16B | -$21.33B | -$4.44B | -$3.69B | |
| Adjustments For Increase Decrease In Trade And Other Payables | $4.0M | $3.46B | $23.0M | $4.41B | $2.86B | $1.58B | $398.0M | $2.50B | $1.89B | |
| Adjustments For Decrease Increase In Trade And Other Receivables | -$120.0M | -$8.05B | -$5.75B | -$17.01B | $2.08B | -$12.45B | $1.80B | -$2.10B | $3.04B | |
| Adjustments For Decrease Increase In Other Assets And Liabilities | -$7.29B | $2.86B | $528.0M | $4.01B | -$3.26B | $4.82B | $4.12B | -$3.43B | -$3.90B | |
| Cash Flows From Used In Increase Decrease In Current Borrowings | $24.49B | $5.49B | -$19.38B | $3.52B | $6.79B | $4.24B | -$15.13B | -$18.03B | $21.54B | |
| Trade And Other Current Receivables | $90.42B | $80.30B | $72.49B | $66.76B | $49.64B | $50.28B | $39.87B | $40.62B | ||
| Trade And Other Current Payables | $35.52B | $30.92B | $26.44B | $25.57B | $23.74B | $16.66B | $14.55B | $16.05B | ||
| Retained Earnings | $315.79B | $265.26B | $215.59B | $175.71B | $156.02B | $144.25B | $128.65B | $113.87B | ||
| Property Plant And Equipment | $1.14B | $76.89B | $66.46B | $62.17B | $57.11B | $52.33B | $54.09B | $57.87B | ||
| Other Noncurrent Liabilities | $39.0M | $3.97B | $2.85B | $2.42B | $2.34B | $2.81B | $2.87B | $3.58B | ||
| Other Noncurrent Assets | $12.0M | $1.63B | $800.0M | $894.0M | $834.0M | $844.0M | $946.0M | $1.03B | ||
| Other Current Liabilities | $45.49B | $42.90B | $39.47B | $33.99B | $30.49B | $29.38B | $24.35B | $22.67B | ||
| Other Current Assets | $30.14B | $22.56B | $20.07B | $13.90B | $14.51B | $13.80B | $12.54B | $14.30B | ||
| Noncurrent Liabilities | $298.0M | $10.93B | $5.02B | $8.29B | $9.04B | $4.44B | $25.53B | $29.45B | ||
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | $10.39B | $1.06B | $660.0M | $3.67B | $4.96B | $328.0M | $813.0M | $2.55B | ||
| Noncurrent Assets | $242.88B | $139.47B | $117.60B | $110.97B | $117.24B | $101.87B | $110.93B | $115.96B | ||
| Liabilities | $1.83B | $106.97B | $90.86B | $102.30B | $92.43B | $77.25B | $85.23B | $99.14B | ||
| Investment Accounted For Using Equity Method | $56.0M | $4.20B | $4.70B | $4.32B | $3.38B | $2.76B | $2.53B | $2.10B |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | $6.0M | $1.06B | $82.0M | $370.0M | $85.0M | $131.0M | $1.27B | $139.0M | $44.0M |
| Proceeds From Sales Of Investments Other Than Investments Accounted For Using Equity Method | $3.27B | $129.78B | $112.81B | $77.77B | $79.53B | $111.70B | $76.29B | $64.04B | $71.60B |
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | $7.26B | $1.39B | -$9.36B | -$701.0M | $12.75B | -$241.0M | -$349.0M | -$1.29B | -$650.0M |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $224.0M | -$59.0M | $286.0M | $733.0M | $113.0M | -$25.0M | $35.0M | $57.0M | -$492.0M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Diluted Earnings Loss Per Share | $0.79 | $66.80 | $54.17 | $141.69 | $103.65 | $117.40 | $113.09 | $59.00 | $72.09 |
| Basic Earnings Loss Per Share | $0.79 | $66.93 | $54.28 | $142.08 | $103.94 | $117.63 | $113.28 | $59.13 | $72.24 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Other Operating Income Expense | $4.36B | $4.20B | $5.91B | $2.76B | $982.0M | $4.29B | $1.96B | $788.0M | $1.07B |
| Operating Expense | $118.59B | $95.88B | $82.20B | $84.36B | $78.80B | $78.02B | $62.54B | $64.39B | $64.86B |
| Interest Paid Classified As Financing Activities | $41.0M | $2.27B | $1.85B | $1.35B | $1.32B | $1.61B | $1.61B | $1.33B | $925.0M |
| Interest And Dividend Received | $3.37B | $1.34B | $777.0M | $873.0M | $1.22B | $624.0M | $781.0M | $412.0M | $628.0M |
| Gains Losses On Exchange Differences On Translation Before Tax | $1.35B | -$318.0M | $946.0M | -$214.0M | $706.0M | $311.0M | -$53.0M | -$32.0M | -$339.0M |
| Finance Income Cost | $55.0M | $3.99B | $2.85B | $2.12B | $1.65B | $1.48B | $1.12B | $2.08B | $806.0M |
| Finance Income | $7.55B | $5.71B | $4.28B | $3.08B | $2.62B | $2.46B | $2.28B | $2.90B | $1.59B |
| Finance Costs | $2.83B | $1.71B | $1.43B | $958.0M | $970.0M | $983.0M | $1.16B | $817.0M | $781.0M |
| Dividends Paid Classified As Financing Activities | $78.0M | $6.65B | $4.98B | $4.15B | $4.15B | $3.92B | $4.00B | $3.99B | $3.39B |
| Adjustments For Unrealised Foreign Exchange Losses Gains | $2.0M | -$534.0M | -$939.0M | -$766.0M | $1.86B | -$2.17B | -$1.59B | -$296.0M | $609.0M |
| Adjustments For Sharebased Payments | $424.0M | $407.0M | $397.0M | $592.0M | $584.0M | $521.0M | $389.0M | $454.0M | $350.0M |
| Adjustments For Depreciation And Amortisation Expense | $200.0M | $14.84B | $12.64B | $11.82B | $12.80B | $12.47B | $12.19B | $11.71B | $11.28B |
| Adjustments For Decrease Increase In Inventories | -$12.75B | -$18.45B | -$2.65B | -$9.91B | -$12.40B | -$1.49B | -$4.48B | -$287.0M | -$6.33B |
| Issued Capital | $834.0M | $834.0M | $833.0M | $832.0M | $832.0M | $831.0M | $830.0M | $830.0M | $829.0M |
| Shortterm Borrowings | $38.05B | $12.72B | $7.39B | $27.08B | $23.14B | $16.44B | $12.13B | $25.47B | |
| Share Premium | $11.13B | $10.77B | $9.69B | $9.28B | $8.89B | $8.50B | $8.21B | $7.79B | |
| Reserve Of Sharebased Payments | $19.0M | $1.51B | $1.65B | $1.63B | $1.46B | $1.23B | $990.0M | $1.02B | |
| Longterm Borrowings | $7.86B | $5.99B | $1.28B | $5.75B | $6.30B | $1.30B | $22.00B | $25.09B | |
| Inventories | $832.0M | $63.55B | $48.67B | $50.88B | $45.41B | $35.07B | $33.58B | $29.09B | |
| Increase Decrease Through Sharebased Payment Transactions | $424.0M | $407.0M | $397.0M | $592.0M | $584.0M | $521.0M | $389.0M | $454.0M | $350.0M |
| Increase Decrease Through Exercise Of Options | $194.0M | $805.0M | $157.0M | $334.0M | $269.0M | $11.0M | $0.00 | $1.0M | $1.0M |
Most recent annual filing with the SEC: June 6, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.